These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22654501)

  • 1. Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension.
    Pfennigsdorf S; Ramez O; von Kistowski G; Mäder B; Eschstruth P; Froböse M; Thelen U; Spraul C; Schnober D; Cooper H; Laube T
    Clin Ophthalmol; 2012; 6():739-46. PubMed ID: 22654501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension.
    Stevens A; Iliev ME; de Jong L; Grobeiu I; Hommer A
    Clin Ophthalmol; 2016; 10():635-41. PubMed ID: 27103783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice.
    Pillunat LE; Eschstruth P; Häsemeyer S; Thelen U; Foja C; Leaback R; Pfennigsdorf S
    Clin Ophthalmol; 2016; 10():1759-65. PubMed ID: 27672307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.
    Chen YY; Wang TH; Liu C; Wu KY; Chiu SL; Simonyi S; Lu DW
    BMC Ophthalmol; 2016 Sep; 16(1):162. PubMed ID: 27633513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
    Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
    Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study.
    Feuerhake C; Buchholz P; Kimmich F
    Curr Med Res Opin; 2009 Apr; 25(4):1037-43. PubMed ID: 19290780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Pfennigsdorf S; de Jong L; Makk S; Fournichot Y; Bron A; Morgan-Warren RJ; Maltman J
    Clin Ophthalmol; 2013; 7():1219-25. PubMed ID: 23814459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension.
    Tamçelik N; Izgi B; Temel A; Yildirim N; Okka M; Özcan A; Yüksel N; Elgin U; Altan Ç; Ozer B
    Clin Ophthalmol; 2017; 11():723-731. PubMed ID: 28458511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment.
    Brief G; Lammich T; Nagel E; Pfennigsdorf S; Spraul CW; Ho S
    Clin Ophthalmol; 2010 Oct; 4():1125-9. PubMed ID: 20957059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice.
    Pfennigsdorf S; Eschstruth P; Häsemeyer S; Feuerhake C; Brief G; Grobeiu I; Shirlaw A
    Clin Ophthalmol; 2016; 10():1837-1846. PubMed ID: 27703324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trial.
    Crichton AC; Nixon DR; Simonyi S; Bhogal M; Sigouin CS; Discepola MJ; Hutnik CM; Baptiste DC; Yan DB
    Clin Ophthalmol; 2014; 8():1031-8. PubMed ID: 24920879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: A prospective, open-label, randomized, two-arm, parallel-group study.
    Vetrugno M; Cardascia N; Cantatore F; Sborgia C
    Curr Ther Res Clin Exp; 2004 Nov; 65(6):444-54. PubMed ID: 24672097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
    DuBiner HB; Hubatsch DA
    BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study.
    Nakano T; Mizoue S; Fuse N; Iwase A; Matsumoto S; Yoshikawa K
    Adv Ther; 2015 Sep; 32(9):823-37. PubMed ID: 26424331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting.
    Park KH; Simonyi S; Kim CY; Sohn YH; Kook MS
    BMC Ophthalmol; 2014 Dec; 14():160. PubMed ID: 25519810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial.
    Nixon DR; Simonyi S; Bhogal M; Sigouin CS; Crichton AC; Discepola M; Hutnik CM; Yan DB
    Clin Ophthalmol; 2012; 6():2097-103. PubMed ID: 23269858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of bimatoprost 0.03 percent in untreated glaucoma and ocular hypertension patients: results from a large community-based clinical trial.
    Quinones R; Severin T; Mundorf T
    J Ocul Pharmacol Ther; 2004 Apr; 20(2):115-22. PubMed ID: 15117567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.